Xeris Biopharma Holdings Inc (NASDAQ: XERS)’s stock price has dropped by -0.23 in relation to previous closing price of 2.13. Nevertheless, the company has seen a loss of -5.13% in its stock price over the last five trading days. businesswire.com reported 2024-06-03 that CHICAGO–(BUSINESS WIRE)– #GvokeHypoPen–Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients’ lives by developing and commercializing innovative products across a range of therapies, today announced it presented a post-hoc analysis from its previously published SONICS study on the effects of levoketoconazole (Recorlev®) in adults with Cushing’s syndrome at ENDO 2024 in Boston, June 1-4, 2024. “The results of this analysis suggest that pati.
Is It Worth Investing in Xeris Biopharma Holdings Inc (NASDAQ: XERS) Right Now?
The 36-month beta value for XERS is also noteworthy at 1.82. There are mixed opinions on the stock, with 2 analysts rating it as a “buy,” 2 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for XERS is 137.79M, and at present, short sellers hold a 8.22% of that float. The average trading volume of XERS on June 20, 2024 was 1.42M shares.
XERS’s Market Performance
XERS’s stock has seen a -5.13% decrease for the week, with a 3.66% rise in the past month and a -2.97% fall in the past quarter. The volatility ratio for the week is 4.34%, and the volatility levels for the past 30 days are at 6.28% for Xeris Biopharma Holdings Inc The simple moving average for the last 20 days is -2.73% for XERS’s stock, with a simple moving average of -0.24% for the last 200 days.
Analysts’ Opinion of XERS
Many brokerage firms have already submitted their reports for XERS stocks, with Oppenheimer repeating the rating for XERS by listing it as a “Outperform.” The predicted price for XERS in the upcoming period, according to Oppenheimer is $5 based on the research report published on March 28, 2024 of the current year 2024.
Craig Hallum, on the other hand, stated in their research note that they expect to see XERS reach a price target of $4.50. The rating they have provided for XERS stocks is “Buy” according to the report published on August 28th, 2023.
Jefferies gave a rating of “Buy” to XERS, setting the target price at $4 in the report published on October 21st of the previous year.
XERS Trading at 6.87% from the 50-Day Moving Average
After a stumble in the market that brought XERS to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -34.82% of loss for the given period.
Volatility was left at 6.28%, however, over the last 30 days, the volatility rate increased by 4.34%, as shares surge +6.75% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +5.69% upper at present.
During the last 5 trading sessions, XERS fell by -4.69%, which changed the moving average for the period of 200-days by -9.92% in comparison to the 20-day moving average, which settled at $2.19. In addition, Xeris Biopharma Holdings Inc saw -9.57% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at XERS starting from Schmid John P., who purchase 5,400 shares at the price of $1.91 back on May 10 ’24. After this action, Schmid John P. now owns 16,400 shares of Xeris Biopharma Holdings Inc, valued at $10,314 using the latest closing price.
Schmid John P., the Director of Xeris Biopharma Holdings Inc, purchase 4,500 shares at $2.16 during a trade that took place back on Mar 14 ’24, which means that Schmid John P. is holding 11,000 shares at $9,720 based on the most recent closing price.
Stock Fundamentals for XERS
Current profitability levels for the company are sitting at:
- -0.26 for the present operating margin
- 0.8 for the gross margin
The net margin for Xeris Biopharma Holdings Inc stands at -0.38. The total capital return value is set at -0.17. Equity return is now at value -617.16, with -19.58 for asset returns.
Based on Xeris Biopharma Holdings Inc (XERS), the company’s capital structure generated 1.04 points at debt to capital in total, while cash flow to debt ratio is standing at -0.18. The debt to equity ratio resting at -25.53. The interest coverage ratio of the stock is -3.28.
Currently, EBITDA for the company is -30.85 million with net debt to EBITDA at -5.76. When we switch over and look at the enterprise to sales, we see a ratio of 3.04. The receivables turnover for the company is 4.58for trailing twelve months and the total asset turnover is 0.51. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.37.
Conclusion
In summary, Xeris Biopharma Holdings Inc (XERS) has had a bad performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
